Swallowable robot-camera could spot stomach cancer early
NCT ID NCT07323186
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new, less invasive way to screen for stomach cancer using a magnetic-guided video capsule that patients swallow. The capsule is steered by a robot and uses AI to check the stomach for suspicious spots. Researchers will compare its accuracy to standard endoscopy in 100 adults aged 50-74 who are already having a colonoscopy.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Magnetically controlled video capsule endoscopy (MC-VCE) device
- What this could lead to
- If successful, this could offer a less invasive, more accessible screening method for early stomach cancer, potentially improving survival rates.
- What could go wrong
- This is an early-stage study with only 100 participants, and the capsule may miss lesions that standard endoscopy finds. It is not yet proven for widespread screening.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Dec 2025
An estimate. Start dates often move.
- Expected to finish
-
Jun 2026
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 74 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Male or female patient, * Aged between 50 and 74 inclusive with a life expectancy of at least 10 years, * Undergoing screening or surveillance colonoscopy (for colorectal cancer or polyps) * Patient who has received verbal and written information as well as a patient booklet on the VCE-CM examination and has given their written informed consent. * Patient affiliated with a social security scheme * Effective contraception throughout the study for women of childbearing age Exclusion Criteria: * Patients who have had or currently have the following (items from the TOGAS pilot study/specific to endoscope use) will not be included in the study: * An EOGD in a high-volume endoscopy centre within the last 3 years * Known gastric cancer * Known genetic cancer syndromes * Previous gastrectomy or bariatric gastric surgery * Known gastric precancerous condition (gastric atrophy, intestinal metaplasia, dysplasia) * Acute gastrointestinal haemorrhage in the last 4 weeks * A coagulation disorder or medication that prevents biopsy sampling * A risk associated with sedation or anaesthesia * Severe heart disease * An inability to actively consent to participation in the study, and patients under guardianship or legal protection. Pregnant or breastfeeding patients will not be included. Patients with the following conditions (specific to VCE-CM examination) will not be included in the study: * Swallowing disorders or known gastroparesis * A history of digestive surgery * Clinical or radiological signs suggestive of narrowing of the digestive tract * An occlusive or sub-occlusive condition, a known or suspected history of stenosis or digestive fistula * Left heart failure with orthopnoea * Overweight (\> 135 kg) * Reduced mobility (i.e. unable to transfer or move themselves) * Persons with pacemakers, defibrillators or metallic foreign bodies (with the exception of dental implants) will not be included in order to avoid interference with the robot.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Diagnosis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Nantes University Hospital
Nantes, 44000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI replace surgery for staging bladder cancer?
- AI reads routine heart tests to predict artery blockages
- Can a glowing mouthwash spot oral cancer before biopsy?
- Can a targeted therapy tame hard-to-treat stomach and esophageal cancers?
- Artificial intelligence may detect Children's heart disease from a routine ECG
- Engineered immune cells take aim at Hard-to-Treat cancers